GEN1078 / Genmab - LARVOL DELTA

A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=3 | Terminated | Sponsor: Genmab | Trial completion date: Oct 2027 ➔ Jun 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Oct 2027 ➔ Jun 2025; The sponsor has made the decision to terminate further development of GEN1078 based on emergent safety observations related to the overall benefit-risk profile of GEN1078

Trial completion date • Trial primary completion date • Trial termination • Solid Tumor

A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=3 | Active, not recruiting | Sponsor: Genmab | Recruiting ➔ Active, not recruiting | N=180 ➔ 3

Enrollment change • Enrollment closed • Oncology • Solid Tumor

A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=180 | Recruiting | Sponsor: Genmab | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=180 | Not yet recruiting | Sponsor: Genmab

New P1/2 trial • Oncology • Solid Tumor